Widespread endotheliopathy in adults with cyanotic congenital heart disease
Related Experiment Video
Updated: May 1, 2026

Isolation of Endocardial and Coronary Endothelial Cells from the Ventricular Free Wall of the Rat Heart
Published on: April 15, 2020
Rachael L Cordina1, Shirley Nakhla2, Shamus O'Meagher3
11Department of Cardiology,Royal Prince Alfred Hospital,Sydney,Australia.
Insights
Adults with cyanotic congenital heart disease exhibit impaired endothelial function in both systemic and retinal vessels. Reduced endothelial progenitor cells may contribute to this widespread endotheliopathy.
Area of Science:
- Cardiovascular Medicine
- Vascular Biology
- Congenital Heart Disease
Background:
- Cyanotic congenital heart disease (CCHD) is linked to functional limitations and vascular complications.
- Endothelial dysfunction in adults with CCHD is not well understood.
- This study aimed to characterize endothelial function in this patient population.
Purpose of the Study:
- To assess endothelial function in adults with CCHD.
- To investigate nitric oxide-dependent vascular responses in CCHD patients.
- To explore potential contributors to endothelial dysfunction in CCHD.
Main Methods:
- Evaluated flow-mediated dilatation (FMD) of the brachial artery in 14 adults with CCHD and controls.
- Assessed dynamic retinal vessel responses to flickering light.
- Measured plasma endothelin-1, asymmetric dimethylarginine (ADMA), and circulating endothelial progenitor cells (EPCs).
Main Results:
- FMD was significantly lower in CCHD adults (4.0%) compared to controls (7.2%).
- Retinal arterial and venous dilatory responses were impaired in CCHD patients.
- Elevated endothelin-1 and ADMA levels, with reduced EPCs, were observed in CCHD adults.
Conclusions:
- Adults with CCHD demonstrate impaired endothelial function in systemic arteries and retinal vessels, indicating a generalized endotheliopathy.
- Reduced numbers of endothelial progenitor cells may play a role in the observed endothelial dysfunction.
- Findings suggest a need for further investigation into vascular health in CCHD adults.
Introduction:
Cyanotic congenital heart disease is associated with functional limitation and vascular events. The nature and extent of endothelial dysfunction in cyanotic adults is poorly understood. We sought to characterise endothelial function in this setting.
Methods:
A total of fourteen adults with cyanotic congenital heart disease (40±3 years) together with age- and sex-matched healthy controls underwent assessment of nitric oxide-dependent vascular responses, including flow-mediated dilatation of the brachial artery and dynamic vessel analysis of the retina in response to flickering light. Plasma levels of the endothelium-derived vasoconstrictor endothelin-1 and the nitric oxide antagonist, asymmetric dimethylarginine, were measured. Circulating endothelial progenitor cells were assessed by flow cytometry.
Results:
Flow-mediated dilatation was significantly lower in cyanosed adults than controls (4.0±0.8 versus 7.2±1.0%, p=0.019, n=11 per group). Retinal arterial and venous dilatory responses were also impaired (2.9±0.8 versus 5.0±0.6%, p=0.05 and 3.4±0.3 versus 5.2±0.7%, p=0.04, n=13). Serum levels of endothelin-1 and asymmetric dimethylarginine were higher in cyanosed adults (3.0±0.6 versus 1.1±0.1 pg/ml, p=0.004 and 0.68±0.05 versus 0.52±0.02 μmol/L, p=0.03, n=11). Endothelial progenitor cells (CD34+CD45dimCD133+KDR+) were reduced in those with chronic cyanosis (17±4 versus 40±6 per million white blood cells, p=0.005, n=11).
Conclusions:
Endothelial function is impaired in the systemic arteries and retinal vessels in adults with cyanotic congenital heart disease, suggesting a widespread endotheliopathy. Diminished numbers of endothelial progenitor cells might potentially contribute to these observations.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Endocarditis II: Clinical Features of Infective Endocarditis
Cardiomyopathy II: Dilated Cardiomyopathy
Endocarditis I: Introduction
Heart Failure III: Clinical Manifestations
Cardiomyopathy IV: Restrictive Cardiomyopathy

